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1. Introduction
Chronic total occlusion (CTO) of coronary arteries is one of the most challenging PCI, usual‐
ly defined as more than three-month-old obstruction of a native coronary artery. This coro‐
nary lesion subset is a frequent finding in patients with coronary artery disease (CAD) as
CTOs have been reported in approximately one-third of patients undergoing diagnostic cor‐
onary angiography. However only 7-15% of CTOs were treated with percutaneous coronary
intervention (PCI) [1] (Figure 1). Perhaps for the fact that procedural success is hampered by
the difficulties associated with crossing and/or dilating the occluded segment with guide‐
wires and recanalization devices and by a high incidence of restenosis and reocclusion.
Despite these obstacles, several studies have documented that successful PCI of CTOs leads
to an improvement in anginal status, normalization of functional tests, improvement of left
ventricular function and avoidance of coronary artery bypass graft surgery (CABG) [2-6].
Patients with untreated CTOs face a threefold increase in cardiac mortality or complications
in case of future acute events [7-9].
Historically,  a  procedural  success  rate  of  60-70%  was  achieved  using  anterograde  ap‐
proach [6]. Nowadays, specifically trained operators are able to improve the rate of CTO
recanalization thanks  to  several  new techniques  and dedicated device  developments.  In
particular, the retrograde CTO PCI approach, that was first mastered by Japanese opera‐
tors,  has  evolved  rapidly,  resulting  in  higher  success  rates,  shortened  procedural  time
and reduced exposure to radiation.
© 2013 Giubilato et al.; licensee InTech. This is an open access article distributed under the terms of the
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It should keep in mind that reopening of a CTO needs to be carefully considered in the
presence of symptoms or objective evidence of viability/ischaemia in the territory of the
occluded artery.
The aim of this chapter will be to provide a systematic overview of the current state-of-the
art in percutaneous recanalization of CTO, to enhance the understanding of this complex
procedure and, consequently, promote safe and effective PCI for patients who present with
this lesion subset. Specifically, after a brief introduction about CTO anatomy and defini‐
tions, the chapter will be divided into five paragraphs that address the most important clini‐
cal and technical aspects of CTO PCI. In the first paragraph the complex clinical CTO
decision-making process will be described. This crucial step consists in the evaluation of
clinical indication, patient selection and revascularization strategies. In the second para‐
graph, specific tools for CTO recanalization will be illustrated focusing on improvements in
guidewire and dedicate device technology, responsible for improved procedural success in
PCI of CTO. A further paragraph will be dedicated to the stent choice for the treatment of
CTO. In fact, there is overwhelming evidence in the literature that drug eluting stent (DES)
rather than bare metal stent (BMS) reduce significantly the restenosis and reocclusion rates
after recanalization of CTOs. The fourth paragraph, will deal with the description of all tech‐
niques to cross CTO by anterograde and retrograde techniques. In this paragraph, the atten‐
tion will be focused on common pitfalls and difficulties and related tips and tricks. Finally,
the last paragraph will be focused on the strategies to prevent and treat the possible proce‐
dural complications including complications related to vascular access or to procedure such
as coronary dissection, perforation or rupture and coronary thrombosis.
Figure 1. Diagnostic catheterization results stratified by treatment strategy. Adapted from Christofferson et al. [1]
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2. CTO anatomy and definitions
A deeper understanding of CTO histopathology might offer insights into the development
of new techniques and procedural strategies. The occluded part of the lumen in CTOs con‐
sists of two types of tissue: atheromatous plaque and old thrombus (Figure 2). The respec‐
tive amount of these items are largely dependent on CTO formation which may be grossly
classified as the two following phenomena:
1. The late organization and development of an acute occlusion due to a plaque rupture,
generally apart from the maximal narrowing area.
2. The progressive occlusion of a long term and high-degree stenosis (with a large amount
of plaque and sometimes several layers of additional thrombi).
Figure 2. The two mechanisms of CTO formation: A) late evolution of an acute occlusion of an eccentric stenosis B)
progressive occlusion of a long standing concentric stenosis.
The histopathology of CTOs was comprehensively described by Srivatsa and coll. in 1997
[10]. These lesions are characterized by a mix of luminal plaque, thrombin, fibrin, inflamma‐
tory cells and neovascular channels (Figure 3). The occlusive thrombus is mainly composed
of collagen-rich extracellular matrix, intra and extracellular lipids, smooth muscle cells and
mixed components, including a small quantity of cholesterol, dense collagen and calcium
deposits. The core composition correlates with the CTO age. Older occlusions have higher
concentration of fibrocalcific material (defined as “hard plaques”), while CTOs visible for
less than one year have more cholesterol clefts and foam cells among less fibrous materials
(defined as “soft plaque”). Typically CTOs may be classified as soft, hard or a mixture of
both. Hard plaques are more prevalent with an increasing CTO age (> 1 year old) [11].
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Figure 3. CTO plaque components.
The intraluminal process of plaque and thrombus organization is often followed by the so
called “negative remodeling”. This event usually leads to an artery vessel shrinkage, which
is mainly observed in CTOs older than 3 months. The negative remodelling process is con‐
nected to the replacement of soft plaque tissue with fibrous one, mainly in the middle sec‐
tion of the occlusion [12]. Another important CTO feature is the extensive process of
“neovascularization” which increase with occlusion age. In CTOs that are less than one year
old the new capillary formation is greater in the adventitia. In CTOs that are more than one
year old there is a rich neovasculature network that often traverses the vessel wall (bridging
collaterals) [13]. Neovascular process may usually lead to the formation of relatively large
capillaries (from 100 to 500 µm) that are defined as “microchannels” (Figure 4). These ves‐
sels can frequently be found through the CTO’s body and can partially recanalize the distal
lumen [14]. Guidewires may use microchannels as a passage to reach the distal vessel, hence
they may have an important therapeutic value. Microchannels might also communicate with
vasa vasorum and facilitate an extra-luminal pathways of collaterals o the distal part of the
occluded segment, giving the typical aspect of “caput medusae” that is usually a sign of an
old and difficult lesion to cross. Moreover, CTOs usually present a higher concentration of
fibrous tissue at the proximal and distal parts of the lesion. These areas create a “fibrous
cap” which is the hardest part of the plaque that surrounds a softer core of organised throm‐
bus and lipids. Therefore, there are four components of CTO to take into consideration [15]:
proximal cap, calcifications, microvessels and distal cap.
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Figure 4. CTO microvessels. This image shows a healed total occlusion (arrowheads) with vascular channels (asterisks)
surrounded by a rich collagen matrix (yellow). Adapted from Hoye A [15].
The temporal  criterion used to  define a  CTO has  varied widely through the litterature,
typically ranging from > 2 weeks [16] to > 3 months [17]. Furthermore, any definition of
CTO must include different  elements such as the degree of  lumen narrowing,  consider‐
ing if  any antegrade blood flow is  present.  According to  the  consesus  documents  from
the EuroCTO Club, lesions can be classified as CTOs, when there is TIMI 0 flow within
the occluded segment and angiographic or clinical evidence or high likelihood of an oc‐
clusion duration > 3 months [18].
CTOs  are  characterized  by  significant  atherosclerotic  vessel  narrowing  with  a  lumen
compromision that results in either complete interruption of antegrade blood flow as as‐
sessed  by  coronary  TIMI  flow (grade  0),  also  known as  “true”  total  occlusion,  or  with
minimal contrast penetration through the lesion without distal vessel opacification (TIMI
grade 1 flow), frequently referred to as “functional” total occlusions. However, the iden‐
tification  of  TIMI  0  flow  is  not  as  straightforward  as  in  recent  post-MI  occlusions,  for
which the TIMI classification was originally developed because antegrade contrast filling
of the segment beyond the occlusion does not preclude TIMI 0 flow within the occluded
segment. Indeed, particular conditions such as the presence of ipsilateral bridging collat‐
erals may give antegrade flow and the false impression of a functional incomplete occlu‐
sion  but  they  are  true  CTO.  Their  presence  should  be  differentiated  from TIMI  0  flow
within  the  occluded  segment  by  careful  assessment  in  different  angiographic  planes.
Moreover, the presence of intraluminal channels certainly plays a role in crossing the oc‐
clusion;  antegrade contrast  filling of  the  segment  beyond the  occlusion flow,  in  the  ab‐
sence  of  ipsilateral  bridging  collaterals  and  even  when  the  occluded  vessel  segment
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shows no intraluminal  contrast  filling,  indicates  a  functional  and not  a  true CTO.  Only
meticulous filming and a vigorous contrast injection with a well  engaged catheter allow
us to  conclude that  TIMI flow is  0  within the  occluded segment  and the  lesion should
then be classified as a CTO [19]. In absence of serial angiograms, the duration of CTO is
difficult  to  establish with certainty and it  might  be estimated from available  clinical  in‐
formation related to the timing of the event that caused the occlusion: acute MI or sud‐
den  change  in  angina  pattern  with  ECG  changes  consistent  with  the  location  of  the
occlusion.
Since the time of the occlusion cannot be known, CTOs are usually distinguished into three
levels of certainty:
a. Certain (angiographically confirmed): the minority of cases where a previous angio‐
gram (for instance before a previous CABG operation, or after an acute myocardial in‐
farction) has confirmed the presence of TIMI 0 flow (3 months prior to the planned
procedure);
b. Likely (clinically confirmed): an acute myocardial infarction in the territory of the occlud‐
ed artery distribution or acute coronary syndrome or deterioration of anginal threshold
without other possible culprit arteries ≥ 3 months before the current angiogram;
c. Possible  (undetermined):  a  CTO with  TIMI  0  flow and angiographic  anatomy sug‐
gestive of long-standing occlusion (collateral development, no contrast staining) with
stable  unchanged  anginal  symptoms  in  the  last  months  or  silent  ischaemia  or,  in
case of  recent acute ischaemic episodes (acute myocardial  infarction or unstable an‐
gina or worsening effort angina), with the presence of a culprit artery different from
the occluded vessel.
3. Decision-making process for patients affected by CTO
The clinical presentation of CTOs can be quite variable ranging from patients with stable an‐
gina to patients with silent ischemia or heart failure of ischaemic origin, or those undergoing
primary PCI due to acute occlusion in a different culprit vessel, in whom a CTO is discov‐
ered as an incidental finding.
Several factors are associated with CTO clinical presentation such as the presence of oth‐
er concomitant coronary lesions, the amount of CTOs related to myocardial viability, the
severity  and extension of  CTO related  to  myocardial  ischemia  and finally  the  coronary
artery involved.
Generally, asymptomatic patients, are more reliable to be left on medical therapy rather than
being percutaneuosly revascularized, especially if these patients have one vessel disease or a
previous PCI, which has been performed in another coronary vessel. Moreover, older pa‐
tients often exert low level of physical activity which might not lead to angina symptoms,
underestimating the real burden of myocardium at risk. However, we know that this thera‐
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peutic strategy might not be clinically appropriate but the decision to treat a CTO in an
asymptomatic patient should be driven by a non-invasive functional imaging test, in order
to clarify the amount of myocardial viability and severity/extension of myocardial ischemia.
On the other hand symptomatic patients represent the greatest challenge for the clinical de‐
cision making, because there are different scenarios which need to be considered:
a. When the CTO is the only culprit lesion in the coronary tree, and presence of viability/
ischemia by non invasive functional test has been shown, PCI is highly recommended
especially if likelihood of success has been estimated >60%. Moreover, if PCI is unsuc‐
cessful, re-attempt might be performed 2-3 months later after first failure. Conversely,
coronary artery bypass graft might be performed to guarantee a complete revasculari‐
zation, especially in case of a large myocardial ischemia or in case of refractory symp‐
toms. Underestimating the CTO clinical impact in a single vessel disease patient might
be led to “catastrophic consequences”. Indeed, although the CTO might be supplied by
collateral circulation without ischemia at rest, acute donor vessel occlusion might cause
a larger myocardial necrosis with a poor prognosis for the patients.
b. It is not rare to see patients with a CTO angiographically documented few years before
and without other coronary vessel diseases, which start to be symptomatic for effort an‐
gina only many years after the angiographic documentation is shown. In these cases,
symptoms and myocardial ischemia could be related to the disease progression in ves‐
sels different from CTO, progression of disease in the donor artery, or to a reduction of
blood supply from collateral circulation due to coronary collateral vasospasm [20].
c. In case of multivessel disease, the presence of a CTO should not be a sufficient reason to
deny percutanoeus revascularization in the absence of significant left main disease and
when the other lesions are suitable for PCI. Indeed, if the decision to perform a PCI is
taken, a staged approach should be a reasonable strategy in order to avoid excessively
long procedures and the use of large amount of contrast media. In this case considera‐
tion of which artery to tackle first, should be based on its importance. When complete
revascularization is to be achieved, it is suggested to start PCI at the CTO vessel. As in
case of the failure attempt, patient might be fully revascularized by surgery. Inversion
of collateral flow direction through the recanalised CTO may protect myocardium at
risk during treatment of lesions in the collateral donor vessel. Conversely, in many pa‐
tients treatment at first of non occluded vessel may improve collateral visualization, sig‐
nificantly contributing to success of CTO recanalization. However, this strategy should
be reserved to those patients in whom CTOs are likely to be successfully performed.
d. Patient might also present two CTO vessels at the same time. In these cases if CTOs an‐
giographic characteristics are favourable and the patient does not present any clinical
contraindications such as renal failure or other comorbidities, PCI may be performed on
both CTOs during the same procedure, paying careful attention to the amount of con‐
trast mean administered and to the duration of radiations exposure.
CTO decision-making process requires an individualized risk/benefit analysis, considering
clinical, angiographic and technical features:
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1. clinical: patient’s age, symptoms severity, associated co-morbidities (chronic obstructive
pulmonary disease, diabetes mellitus, chronic renal insufficiency), left ventricular ejec‐
tion fraction, associate valve disease and overall functional status.
2. angiographycally: the extent and complexity of coronary disease (left main disease, bi‐
furcation lesion, ostial lesion, long lesion, severe calcification), often not recognized be‐
fore recanalization is performed.
3. technical: to evaluate percentage of success of revascularization preventing complica‐
tions and considering restenosis rate on the basis of a total stent length required and
vessel diameter size.
Regarding clinical features, a great concern is the patients’ age. Indeed, in case of octogenari‐
ous patients, the operator should not expect any improvement of prognosis, and thus percuta‐
neous attempt of CTO is supposed to be undertaken, only in presence of severe ischemia or
refractory symptoms. Another clinical feature to evaluate is the renal function. Parameter used
to assess renal impairment is the serum level of creatinine, or the glomerular filtration rate as
measured by Cockcroft-Gault formula [21]. However, the risk of contrast induced nephrop‐
athy does not relate only to renal impairment before the procedure, but also to left ventricular
ejection fraction (LVEF) and the presence of associated comorbidities such as diabetes mellitus
and older age. The LVEF assessment is also relevant to consider the opportunity in which the
left ventricular assistance device might be used during the procedure, such as intra aortic bal‐
looning pumping (IABP). IABP displaces blood during diastole augmenting diastolic pres‐
sure. This augmented pressure wave carries blood flow up to the coronary arteries and can
increase coronary blood flow across some coronary narrowing and, in some circumstances,
even improving collateral flow to distal CTO coronary vessels. Immediately before systole, the
deflation of the counter-pulsation balloon creates a negative space, reversing aortic flow and
reducing ventricular after load and, hence, myocardial oxygen demand. Yoshitani, et al. dem‐
onstrated that IABP does not increase diastolic pressure distal to severe coronary stenosis, and
thus, the major benefit of IABP in such patients with coronary artery disease is the reduction of
myocardial oxygen demand [22]. The presence of left main stenosis might not represent a con‐
traindication for CTO PCI. Indeed, the percutaneous treatment for CTO at first, might protect
the patient from procedural ischemia during left main PCI, in case of contraindications to sur‐
gery. Nevertheless, in these cases it is always recommended to use IABP if Euroscore is ≥ 6 [23].
In patients underwent previous surgical revascularization, CTO treatment is a dilemma and
the choice between performing native vessel and graft recanalization is not always easy, es‐
pecially in case of old degenerated graft. Furthermore, even when the graft is not occluded
but severely diseased at the level of the anastomosis PCI of the graft might be overtaken by
recanalization of the native vessel if the occlusion is easy to approach. Moreover, it has been
shown that myocardial ischemia might also occur in presence of a patent graft due to endo‐
thelial dysfunction [24]. Indeed, despite the presence of a patent and non-occlusive graft, re‐
gional myocardial blood perfusion might be still compromised, leading to ischemia.
A consensus document from EuroCTO Club [18] underlines that “PCI CTO should be at‐
tempted after careful review of clinical history, results of provocative tests, coronary anato‐
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my and personal experience” and “with average recanalization success rate of >70% in
experienced hands with contemporary techniques the presence of a CTO should not be suf‐
ficient reason to switch from PCI to surgery in multivessel disease”.
3.1. Non invasive detection of myocardial viability
The non invasive assessment of myocardial viability has proved clinically useful for distin‐
guishing hibernating myocardium from irreversibly injured myocardium in patients with
chronic ischemic heart disease who exhibit marked regional and global left ventricular dys‐
function [25]. The accurate noninvasive determination of myocardial viability is critically
important for clinical decision making [26]. It makes allowance for the selection of patients
with CAD and resting left ventricular dysfunction who benefit from revascularization strat‐
egies. Patients with substantial zones of viability and asynergic myocardium should demon‐
strate better function and overall better outcomes after revascularization compare with
patients affected by a ventricular dysfunction related to large myocardial scar.
Thallium-201 is the imaging agent most frequently used with single photon emission tomog‐
raphy (SPECT) imaging for determination of myocardial viability. The reason is that the de‐
layed uptake of thallium-201 on rest-redistribution imaging is related to myocardial cellular
integrity. Several groups have shown that approximately 70% of segments showing >50% or
>60% thallium-201 uptake on 3- to 4 hour rest thallium-201 redistribution scintigrams will
demonstrate improved systolic function after revascularization [27-28]. The greater the num‐
ber of viable segments detected preoperatively, the greater the improvement in LVEF post‐
operatively.
Although, 99mTc-labeled perfusion agents, such as sestamibi and tetrofosmin, do not show
any significant redistribution over time after being injected intravenously, several studies
have shown comparable accuracy for viability detection between these agents and thalli‐
um-201 [29-30]. This is thought to be due to high extraction of these tracers in the region of
low flow in which myocites are viable. These agents bind to the mitochondrial membrane
and require an intact mitochondrial membrane potential for intracellular binding.
Positron emission tomography (PET) is considered to be the standard of reference for nonin‐
vasive detection of viability with nuclear cardiology techniques. A myocardial zone of asyn‐
ergy is determined to have preserved viability when there is a “mismatch” between
perfusion and 18F-fluorodeoxyglucose (FDG) uptake. Patients with a “mismatch” pattern
(low blood flow perfusion/high metabolic uptake) will often show improved regional and
global left ventricular function after revascularization, whereas patients with a concordant
reduction in perfusion and FDG uptake, referred to as a “match” pattern, have predomi‐
nantly scar and do not show any significant improvement in regional and global function
after revascularization [31].
Allman et al performed a pooled analysis [32] consisted of 3088 patients in 24 studies report‐
ing viability by use of radionuclide imaging, PET or dobutamine echocardiography, and
long-term survival after revascularization or medical therapy. In patients with predominant
viability, follow-up on medical therapy was associated with very high risk, as demonstrated
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by a 16% annual mortality rate. In similar patients, revascularization was associated with an
80% reduction in annual mortality rate [16% vs 3.2%, p<0.0001), as compared with medical
therapy. Patients with the most severe LV dysfunction derived the greatest benefit from re‐
vascularization, that is the survival benefit associated with revascularization of patients with
viable myocardium increased proportionately with worsening LVEF. The data suggested
that the presence of viable myocardium as defined by noninvasive imaging in patients with
heart failure, is a marker for very high natural history risk, and that risk appears to be signif‐
icantly reduced by revascularization.
3.2. Impact of complete percutaneous revascularization
Complete myocardial revascularization remains a desirable goal to obtain with PTCA or
CABG [33]. However, incomplete revascularization with PCI of the culprit vessel may be the
suitable strategy in selected patients [34]. This may occur, when the vessel, responsible of
ischemia, can be identified, particularly when this vessel is a favourable lesion that serves a
large non-infarct territory, in case of an acute coronary syndrome, left ventricular dysfunc‐
tion due to acute severe ischemia or pre-existing renal failure. Indeed, situations which in‐
volve complex anatomy such as CTOs may be more cumbersome to approach and a proper
planning procedure rather than an hoc angioplasty may be also indicated in such patients.
Hannan et al showed that incomplete revascularization with stenting is associated with an
adverse impact on long-term mortality [35]. Even more important, this author showed that
incompletely revascularized patients with total occlusions, particularly those with no other
incompletely revascularized vessels experienced lower rates of subsequent PCI than other
patients. Although, at first, it seems to be good news for these incompletely revascularized
patients, the fact that they had higher long-term mortality than completely revascularized
patients suggests that they might have benefited from more subsequent revascularization.
Indeed, with the percutaneous approach the presence of a CTO remains the biggest and
most important technical challenge to achieve complete revascularization. Furthermore, as
the procedure of a CTO recanalization still remains time consuming, exposing the patient to
high dose of ionizing radiation and contrast media, any percutaneous treatment in these
subset of patients must be justified on the basis of a strict clinical indication, to improve pa‐
tients’ symptoms and prognosis survival [6]. Taking all that into consideration, stress myo‐
cardial perfusion imaging is an effective means of identifying ischemic and viable
myocardium and its vascular distribution in patients undergoing coronary revascularization
[36-38]. Nuclear data have suggested that adverse events after incomplete revascularization
occur more frequently in patients with perfusion defects [39-41], and that myocardial scin‐
tigraphy is able to provide incremental prognostic information after adjusting for clinical,
angiographic and exercise variables [42]. Recently, we have shown that in patients with a
CTO in a main coronary artery left untreated, patients with either a severe perfusion defect
or ischemia and necrosis at stress myocardial scintigraphy have the worst prognosis in
terms of hard events at 9 years follow-up as compared to patients with normal or near nor‐
mal myocardial scan or only either necrosis or ischemia [43]. In these patients the presence
of another vessel incompletely revascularized beyond that of the CTO artery, did not seem
to change the prognosis at follow-up as shown by the occurrence of hard events in those pa‐
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tients with severely abnormal scans. Moreover, this study provides sufficient evidence that
the absence or presence and type of collaterals do not influence prognosis but rather being
equally distributed in all subsets of patients. It is also interesting to note that normal scans
were rare among the CTO patients accounting for only 6% of all scans; indeed, despite the
presence of well developed collaterals (either by Rentrop or Werner classifications) abnor‐
mal scans were shown in the majority of patients. As shown by Werner and colleagues even
in patients with normal regional LV function, collaterals provide a normal coronary flow re‐
serve in less than 10% [44]. This study highlights how CTO patients need to be assessed ap‐
propriately by means of functional imaging testing before considering medical therapy
instead of revascularization. Conversely, a functional nuclear stress imaging study would
enable a tailored strategy of complete revascularization in those patients with multivessel
disease and incomplete revascularization in which complete revascularization by PCI may
be contraindicated, or difficult to achieve.
Although the concept of hibernating myocardium suggests that it is an adaptive steady
state, potentially reversible with revascularization, several reports have suggested that pro‐
gressive structural and clinical deterioration may occur in this pathophysiologic setting,
with more advanced structural changes being associated with less favourable improvement
after revascularization [45]. Indeed, patients with more advanced abnormalities had less im‐
provement in regional and global function after revascularization suggesting that hiberna‐
tion is an incomplete adaptation to ischemia and that once identified, prompt
revascularization should occur. Consistent with this concept are data from Beanlans et al
[46] who reported that after identification of patients with ischemic cardiomyopathy who
had significantly viable myocardium by PET imaging, a substantial delay in revasculariza‐
tion was associated with death during that delay and absence of post-revascularization LV
functional improvement, as compared with patients undergoing more prompt revasculari‐
zation. These important studies have significant practical implications, suggesting that iden‐
tification of patients with substantial ischemia and viability are not only at long-term risk,
but risk in the short term as well, and that optimal reversibility of LV dysfunction and im‐
provement in symptoms and outcome are dependent on prompt referral for revasculariza‐
tion. These important data might support the concept that viability information can assist in
the selection of patients with CTO and regional left ventricular dysfunction for whom the
most optimal potential outcome will come from PCI rather than medical treatment or surgi‐
cal revascularization if not needed.
Cardiac Magnetic Resonance Imaging (cMRI) has enormous potential thanks to its major at‐
tributes of high image quality and resolution combined with non-ionising radiation. It can
provide high quality diagnostic information about cardiac and valvular function, coronary
anatomy, coronary flow reserve, myocardial perfusion, myocardial viability, contractile re‐
serve and cardiac metabolism. It allows assessment of even subtotal wall motion disturban‐
ces resulting from the consistently high endocardial border definition, and the measurement
of myocardial perfusion can be integrated into the same examination, with the high spatial
resolution of the scans facilitating the determination of the transmural extent of a regional
perfusion deficit.
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Recently the technique of late enhancement with gadolinium contrast agent has been descri‐
bed, in which imaging of the heart is performed 15 minutes after an intravenous injection of
gadolinium. The gadolinium concentrates in the necrotic (acute infarction) or scar tissue
(chronic infarction) because of an increased partition coefficient and the infarcted area be‐
comes bright [47]. There is very close correlation between the volume of signal enhancement
and infarct size in animal experiments of acute infarction. The technique has high resolution,
and can define the transmural extent of necrosis and scar for the first time in vivo. Although
the technique has been recently developed, it has obvious applications in defining whether
infarction has actually occurred in borderline cases. The technique of late enhancement has
also clinical application to the assessment of viability and it is an excellent technique for the
detection and quantification of myocardial infarction as reported by many studies [48-49].
First pass perfusion is the most widely used cMRI-technique for the detection of reduced
myocardial blood flow and yields superior results compared to SPECT [50].
The different noninvasive modalities available to assess myocardial viability interrogate dis‐
tinct pathophysiologic myocite and myocardial processes. The SPECT radionuclide tracers
examine myocite cell membrane integrity, and dobutamine echocardiography assesses re‐
gional ventricular contractile reserve. PET images myocardial blood flow and metabolism,
whereas magnetic resonance hyperenhancement imaging identifies scarred myocardium.
Although no major differences have been identified among the modalities that would sug‐
gest differences in patient management, in a pooled analysis of studies reporting on rates of
regional functional recovery, few years ago Bax et al. [38] reported that the radionuclide
agents are more sensitive and that dobutamine echocardiography was more specific, with
PET having slightly higher overall accuracy for predicting functional recovery [51].
However, in the presence of a CTO and a very low blood flow state due to the occluded ar‐
tery, which is supplied only by small collateral channels, dysfunctional but viable LV seg‐
ments may show a modest inotropic response to dobutamine because of the early
occurrence of ischemia [52]. Indeed, asynergic but viable myocardium usually thickens un‐
der catecholamine stimulation [53]. However, this effect may be limited or even abolished in
the presence of a very flow-limiting CTO, underestimating the amount of myocardial viabil‐
ity in these subsets of patients [54].
More recently contrast-enhanced MRI has shown to be comparable with a PET/SPECT imag‐
ing protocol for the prediction of regional and global functional improvement after revascu‐
larization [55]. However, in the presence of discrepant findings between the modalities, c-
MRI is superior to PET/SPECT for predicting lack of recovery of segmental myocardial
function after revascularization. One of the reason for this finding may be explained by dif‐
ferences in the way the two techniques assess myocardial viability [56]. Indeed, a relatively
small volume of dysfunctional viable tissue may show increased 18F-FDG PET uptake, with
PET indicating viability, whereas the coexistence amount of scar impedes functional recov‐
ery. Although some individual studies may suggest better prediction about functional re‐
covery by one test type over another, such data generally reflect differences in small regions
or segments per patient and do not seem to affect long-term outcomes.
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4. Tools for CTO recanalization
There are four important features of CTO wires:
1. Polymer covers: these are plastic sleeves of flexible but solid material which are applied
directly over the core or over spring coils covering the tip of the wire. Based on the
presence or absence of a polymer, CTO wires are divided in two main categories: poly‐
mer jacket wires (by default also hydrophilic coated) and spring coil wires (some hy‐
drophilic coated and some not).
2. Wire coatings: these affect lubricity and tracking and facilitate smooth movement.
There are two types: hydrophilic and hydrophobic. Hydrophilic coatings attract water
and are applied over polymer and stainless steel, including tip coils. They are thin and
non-slippery when dry and become gelatinous when wet, reducing friction. They usual‐
ly cover the distal 30-35 cm of the wire. Hydrophobic coatings (Dow Corning Silicone)
repel water. No wire flushing is required and they also reduce friction but not to the
same extent as hydrophilic wires. These coatings usually cover the working area of
wire, excluding the tip. There is an inverse relationship between lubricity and tactile
feedback related to the presence or absence of coatings over coils and polymers at wire
tips.
3. Core materials and tapering: the majority of CTO wires have a stainless steel core. Mod‐
ern CTO wires have a transitionless parabolic core grind which provides excellent tor‐
que response and no prolapse points compared to conventional step tapering of non-
CTO wires.
4. Tip stiffness: this ranges from 0.5 to 20 grams. Usually plastic jacket wires are in the low
range of stiffness and spring coil wires cover the whole range. Tip tapering strongly af‐
fects penetration power as the force is applied over a smaller cross-sectional area in ta‐
pered wires.
4.1. Micro-catheters and over the wire balloons
Wires should be used with an over the wire (OTW) balloon or micro-catheter in order to ease
torque in the tip response, preventing flexion, kinking, prolapse of the guide wire, and improv‐
ing penetration ability. They also allow one to modify and reshape the guide wire curve, and
exchange one guide wire for another. Micro-catheters in comparison with OTW balloons may
provide a better tip flexibility, improving wire manipulation due to their larger inner lumen
and hydrophilic coating which reduces friction. They also have the advantage of a radiopaque
marker at the “real catheter tip” which has a flat end. Both of these characteristics help to avoid
advancing too far into the lesion, a mistake that occurs frequently with OTW balloons. Addi‐
tionally, most of the micro-catheters are braided which prevents shaft kinking, especially when
crossing very tortuous vessels, a characteristic that OTW balloons lack. On the other hand mi‐
crocatheters are more expensive and do not offer dilating capacity. The choice between an
OTW balloon catheter and a dedicated micro-catheter depends on the features and CTO com‐
plexity and on the operator’s personal experience. Micro-catheters differ from each other re‐
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garding  construction  characteristics,  as  well  as  flexibility,  pushability,  and  trackability
properties. One of the micro-catheters most generally used is the Finecross which is braided,
hydrophilic coated and has a tapered body. It is available in 130cm and 150cm lengths, for the
antegrade and retrograde approaches respectively.
The Tornus (Asahi Intecc Co., Nagoya, Japan) crossing micro-catheter has been developed to
penetrate severe and hard lesions with greater flexibility and torquability with a rotational
burrowing advancement manually manoeuvred by controlled counter-clockwise rotation.
The Corsair (Asahi Intecc Co., Nagoya, Japan) is a septal dilator catheter used for the retro‐
grade approach. This is a micro-catheter which is dedicated for selective engagement of the
collateral channel. It consists of a tapered tip and screw head structure, which reinforces tor‐
que transmission for the guide wire and creates better back-up support for CTO penetration.
The Corsair provides superior tip flexibility which enables smooth approaches to narrow
tortuous vessels, such as septal channels. Unlike other general micro-catheters, the Corsair
possesses a soft tip with tungsten powder mix and a 0.8 mm platinum marker coil 5 mm
from the tip, which makes it easy to identify the distal tip under fluoroscopy.
The Venture™ Catheter (Velocimed, Minneapolis, Minnesota, USA) is an over the wire, low
profile support catheter, 6F compatible, flexible, torqueable with a radiopaque atraumatic
tip. It has been recently designed to help direct the wire where there are difficult angles,
providing strong support especially in occlusive lesions. It is also available as a rapid ex‐
change device.
The Twin pass (Vascular Solutions, Inc Minneapolis, Minnesota, USA) is a dual access lu‐
men rapid exchange micro-catheter (rapid exchange and over the wire) which helps the
guide wire placement and exchange after reopening the occlusion and gaining access to dif‐
ferent main branches.
The Crusade (Kaneka Corporation, Japan) micro-catheter has the similar design and applica‐
tion of the Twin pass.
4.2. Dedicated devices in clinical use
Many dedicated devices to open CTOs were developed in the past, but most disappeared
because they did not prove superior to conventional CTO procedure equipment. The follow‐
ing dedicated devices are currently in clinical use:
Crosser. The Crosser CTO recanalization system (Flow-Cardia Inc, CA, USA) is comprised of
a generator, transducer, foot switch, and a disposable catheter. Through the generator the
catheter tip vibrates at a rate of 21,000 cycles/sec. This vibration provides mechanical impact
and cavitational effects, which aid in the recanalization of the occluded artery. The catheter
is monorail, hydrophilic, and can be advanced over a standard 0.014 inch guide wire. It is
1.1 mm in diameter, which makes it compatible with 6 Fr guiding catheters, and has a blunt
tip. In a small single centre experience comprising 28 patients (30 lesions) technical success
was obtained in 63% of the occlusions with minor complications [57]. In a single center reg‐
istry of 45 patients with relative complex CTOs success rate was 84% but the use of the de‐
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vice was associated with lower time of procedure, time of fluoroscopy, and contrast load
administration as compared with conventional techniques [58]. In the prospective multicen‐
ter CRAFT registry that enrolled 80 patients where the device was used as a first treatment
choice success rate was 76% [59].
BridgePoint system. The BridgePoint technologies consists of three devices that can be used
alone, or in concert with other wires/devices for rapid and safe CTO crossing and provision‐
al luminal re-entry. The Crossboss catheter is an OTW stainless steel catheter with a round‐
ed tip that can negotiate CTOs by using rapid bi-directional rotation. If the Crossboss, or
conventional wires and devices, gain subintimal/subadventitial position, the flat Stingray
balloon (with an exit port oriented toward the lumen) and Stingray guide wire can be utiliz‐
ed for dedicated lumen re-entry and distal vessel access. The FAST-CTOs pivotal trial enrol‐
led 147 patients with wire-refractory CTOs. Technical success was 77%, 30 day MACE < 5%,
and average procedure time was 105 minutes [60]. Recently, the preliminary European expe‐
rience (42 patients) with this system was reported and the success rate was 67% without any
safety issues [61].
5. The key of success of CTO PCI
The selection of the access route is dependent on the individual patient situation (e.g., severe
peripheral vascular disease, which may mandate a radial approach) as well as on the opera‐
tor’s preference. Guiding catheter size is limited from the radial approach, but the radial ar‐
tery can be easily used for contralateral injection (5 or 6 Fr diagnostic catheters). Most
experts use the femoral approach (90% in Europe) and it has not been shown that either ac‐
cess is preferable except for about 10% of the cases in which even experienced radial opera‐
tors select the femoral route.
Good passive support with coaxial alignment into the coronary artery for active support is
crucial. Passive support is stronger with larger guiding catheters (7 and 8 Fr) while 6 Fr cath‐
eters offer the best balance between active and passive support. For the left coronary system
extra backup–type catheters (Voda left, extra backup, geometric left, left support) are pref‐
erable, although some operators still prefer Amplatz type or even Judkins type catheters, the
latter needing more manipulation to achieve optimal position and back up in complex cases
(Figure 5). For the right coronary artery 6F and 7F catheters can be used with left Amplatz
0.75-2 shapes, hockey stick shapes for gentle superior origins of the RCA, Judkins shape for
slightly inferior origins and internal mammary artery type guiding catheters for upward ori‐
gins (Figure 6). One word of caution is that there is a higher risk of vessel injury at the osti‐
um and first bend of the right coronary artery especially with an Amplats left that has a
tendency to jump into the artery, and with all kinds of 8 Fr catheters. In case of ostial dissec‐
tion, a soft-tipped wire must be selected and steered carefully past the dissection that needs
to be fixed before continuing the procedure. Often the guide catheter has to be changed to
avoid an orientation towards the dissection.
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Figure 5. Guiding catheter selection for left coronary artery; A) normal left main; B) short left main.
Figure 6. Guiding catheter selection for right coronary artery; A) normal origin; B) Shephered’s crook origin; C) low
origin with horizontal course.
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When the distal vessel is mainly filled by retrograde collaterals, or there are bridging collat‐
erals originating near the occlusion that are likely to have their flow impaired after wire-
catheter advancement, contralateral injection is necessary from the beginning of the
procedure. The contralateral approach can also be achieved by puncturing the same groin
with a 4 to 6 Fr catheter, which may allow the procedure to be better tolerated. The opera‐
tors of the EuroCTO Club have used contralateral injection in 62% of cases of their personal
series (range 33-78%) [62].
A floppy wire is often the best initial choice to negotiate the segment proximal to the occlu‐
sion and advance an OTW balloon or microcatheter up to the proximal stump and then ex‐
change it to a stiffer dedicated wire.
Until recently, the standard way of selecting a guide wire was to use a gradual step-up ap‐
proach, which consists of tackling the lesion with a medium-tipped guide wire (3-6 gr) and
then exchanging it for a stiffer one (9-12 gr). Using this approach, a reasonable choice is to
start with a Medium or a Miracle 3 first (Asahi Intecc Co., Nagoya, Japan), then switching to
stiffer wires.
The introduction of very soft tapered polymeric wires such as the Fielder XT dramatically
changed this practice. Soft tapered polymeric wires became the standard to start CTO proce‐
dures; in about 40% of the cases this wire will cross the occlusion taking advantage of invisi‐
ble tiny channels [62]. The current trend is a sharp step up to very stiff tapered spring coil
tapered hydrophilic wires such as Confianza pro 12 gr and PROGRESS 200T to overcome
any hard calcified or fibrotic segments of the occlusion and quickly return to soft polymer/
hydrophilic wires to continue long segment tracking and complete crossing of the CTO. This
strategy significantly reduces procedural time and material consumption. With contempo‐
rary CTO techniques soft polymer wires are of increasing use followed by spring coil stiff
but hydrophilic wires while bare spring coil wires became of secondary importance.
The shaping of a CTO guide wire tip is very important. Usually, a small 40-50° curve, 1.0-2.0
mm from the tip of the wire is needed to penetrate the proximal fibrous cap. In hard spring
coil wires a gentler secondary 15-20° curve, 3.0-4.0 mm proximal to the distal tip is necessary
to navigate into the CTO body, to orient the tip and to cross the distal fibrous cap especially
in vessels bigger than 3.5 mm.
5.1. Single wire techniques
There are three fundamental elements of wire handling: rotating, pushing and pulling. After
entering the proximal cap, one should very gently push while simultaneously keep applying
torque, until the wire slides into the body of the occlusion. The wire should be rotated clock‐
wise and counter clockwise, but not more than 360° in the same direction, in order to keep
good tip control. Uncontrolled wire spinning may result in large dissections that might
make difficult to find the distal true lumen or lead to complications such as wire exit and
perforation or wire entrapment.
If resistance is strong, pushing (advancement of the OTW catheter close to the tip of the wire
to increase stiffness and pushability) may open a false lumen and should be avoided. Apply‐
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ing rotation in combination with appropriate wire selection is the right choice as it will mini‐
mize resistance at the tip.
Wires, especially stiff ones, have the tendency to follow the outer part of the vessel curve
which in tortuous occlusions can easily lead to vessel exit and perforation. It is important to
direct the wire tip towards the inner part of vessel bends. Calcification or occluded stents
are often good markers of the vessel course. Bridging collaterals should be carefully recog‐
nised and avoided as modern wires, especially polymer ones, can easily track these vessels
and lead to major complications if perforated or dilated.
5.2. Parallel-wire technique
The parallel-wire technique was first described by Reifart in 1995 and was further devel‐
oped by Katoh [63]. It is a cornerstone technique in CTO PCI that every operator should be
familiar with. When the first wire enter the false lumen, it is left in place, and a second wire
(typically stiffer and often tapered with different tip bend) supported by an OTW catheter, is
passed parallel to the first wire aiming for the distal true lumen. The initial wire serves as a
marker, occludes the wrong pathway and can potentially modify the anatomy by changing
vessel geometry and smoothening sharp curves.
If the second wire also fails to enter the distal true lumen and follows a different incorrect
pathway, often on the opposite wall, the first wire is withdrawn and steered in the direction
of the true lumen using the second wire as a marker; the so-called “see saw” technique. Oc‐
casionally, three or more wires are used. As in single wire techniques it is of paramount im‐
portance not to over-rotate and push either of the wires, in order to avoid creation of large
dissection and subintimal spaces as well as to avoid wire twisting. Often re-puncturing the
proximal cup or navigating through the occlusion with a difference of fraction of a millime‐
tre is critical for success.
5.3. Techniques with sub-intimal tracking
The STAR technique (sub-intimal tracking and re-entry) was introduced by Colombo [64]
who demonstrated that the technique was feasible and safe. This method involves fashion‐
ing a large “umbrella-handle” shaped bend at the tip of a hydrophilic wire once the wire is
within the dissection flap. Force is then applied to this tip and evenly distributed over a
large surface area, along the length of the umbrella-handle, to break through the sub-endo‐
thelial layer thereby creating a communication between the false lumen and the true lumen.
Carlino [65] introduced the modified STAR technique (guided-STAR technique), by inject‐
ing contrast into the subintimal space in an effort to simplify the original technique and
make it more widely applicable. Once in a dissection plane pure contrast is gently injected
from via an OTW balloon or a micro-catheter drawing a roadmap of the occluded segment.
The injection might cause a coronary dissection whether tubular (a linear morphology con‐
sistent with the vessel outline) or storm cloud (small side branch or bridging collaterals dis‐
section with diffuse contrast extravasation into the adventitia). Sometimes a communication
between the false and true lumen can be created.
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More recently, Carlino [66] proposed the “Microchannel technique”. The idea came from
histological CTO data demonstrating that most occlusions have intra-luminal micro-chan‐
nels with size between 100-500 µm that run within and parallel to the occluded vessel
[67-68]. According to this technique after central puncture of the proximal cap with a very
stiff spring coil wire for a length no longer than 1-2 mm and advancement of a OTW balloon
or a micro-catheter, contrast is injected aiming to enlarge and connect these micro-channels
creating a communication between the proximal and distal true lumens favoring guide wire
crossing through the occlusion. This technique is mostly proposed for straight CTO seg‐
ments with a concave proximal cap that will facilitate central puncture.
Galassi further refined the STAR proposing the “Mini-STAR” technique using the very soft
Fielder polymeric guide wires. The Fielder FC and XT (tapered) can track intra-occlusion
channels navigating though the occlusion. In cases of channel interruption or presence of
harder tissue by forcing the wire when supported by a micro-catheter a J-tip shape is auto‐
matically created within the occlusion. This J tip is smaller compared to the one purposely
created with stiffer polymeric guide wires during the STAR technique allowing “mini sub-
intimal tracking” with the creation of much smaller subintimal spaces. This technique was
successful as a rescue in 97.6% of cases during the same procedure after failure to recanalise
with conventional techniques, and during a second attempt in 84.6% of the cases [69].
5.4. Retrograde approach
The  retrograde  techniques  have  a  long  standing  history.  In  the  late  80s  Hartzler  intro‐
duced the retrograde dilatation of native artery stenosis proximal to a distal SVG anasto‐
mosis. In the early 90s retrograde wire crossing of CTOs via saphenous vein graft (SVG)
grafts were attempted. In late 90s the invention of the bilateral approach led to the mark‐
er  wire  technique where the retrograde wire  was used as  a  roadmap for  the antegrade
wire.  In  the  early  2000s  initial  attempts  to  break  the  distal  cap  with  balloons  were  at‐
tempted  and  in  2005  Katoh  pioneered  the  field  introducing  the  Controlled  Antegrade
and Retrograde subintimal  Tracking (CART) technique [70]  establishing the modern era
of retrograde CTO recanalisation. Beyond the concept of retrograde dilatation within the
occlusion to facilitate antegrade wire crossing, the novelties introduced in this procedure
was  the  retrograde  balloon  dilatation.  Indeed,  the  principle  of  this  technique  is  retro‐
grade penetration and dilatation of the occlusion, most often close to the distal cap, thus
creating a  large  target  (subintimal  space)  facilitating antegrade wire  crossing.  In  the  re‐
verse  CART,  the  principle  is  the  same as  the  CART technique  with  the  difference  that
the subintimal space is created with antegrade balloon dilatations facilitating the crossing
of  the  occlusion  with  the  retrograde  wire.  Currently,  this  is  the  dominant  technique  in
the  retrograde  CTO  approach  [71].  IVUS  guidance  for  the  connection  of  the  antegrade
and retrograde subintimal spaces [72],  led by Japanese operators,  significantly contribut‐
ed  to  our  understanding  of  these  techniques,  but  did  not  receive  widespread  adoption
due  to  its  inherent  complexity  and  cost.  More  recently,  a  variety  of  modifications  to
these cornerstone techniques have been introduced such as subintimal space stabilization
with stents (stent CART technique after septal overdilatation and retrograde stenting and
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the stent reverse-CART technique) introduced by Sianos [73].  The retrograde wire cross‐
ing technique (crossing of the occlusion purely retrograde without the need for creation
of subintimal spaces), which accounts for almost 30% of successes, as well as the marker
wire technique should also be kept in mind as simpler retrograde techniques which can
always prove helpful [74].
6. The stent choice for CTO treatment
Several randomized studies have compared balloon angioplasty with stent implantation for
the treatment of CTOs (Figure 7). Although these trials have shown diverse results regard‐
ing entry criteria, antithrombotic regimen and trial design, their findings are remarkably
concordant. The restenosis rate was reduced from 70% in the balloon treated groups to 30%
in the stent groups, with a corresponding reduction in the need for revascularization and
with no increased risk of stent thrombosis. Also the rate of reocclusion was significantly re‐
duce by stent implantation. The introduction of DES has determined a significant reduction
in restenosis and re-occlusion as compared to BMS.
 
Figure 7. Restenosis after percutaneous recanalizzation of CTO: an overview of POBA versus stent implantation
randomized trial
It is advisable to use DES with a very low late lumen loss are in CTOs, as these lesions have
a large plaque load and the compression of these plaques within the adventital space pro‐
motes intimal proliferation and therefore high restenosis and re-occlusion rates as previous‐
ly demonstrated with BMS [75-81].
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6.1. Paclitaxel-eluting stents (PES) for CTOs
Werner et al. [82] evaluated the efficacy of PES in 48 consecutive patients with CTOs com‐
pared with a matched group of 48 patients previously treated with BMS. Patients matching
was performed on the basis of a history of diabetes mellitus, prior MI, diameter and number
of stents implanted, lesion location and left ventricular function. The PES-treated group had
significantly fewer adverse events relating to the reduced need for repeat revascularization;
the advantage of PES over BMS was also significant both in diabetic and non-diabetic pa‐
tients. Angiographic follow-up demonstrated the efficacy of the PES with a significantly
smaller late lumen loss in the PES-treated group and significantly less restenosis (8% vs
51%) and reocclusion (2% vs 23%).
Two additional registries studied the role of PES in CTOs: among 65 patients with CTOs in
the international WISDOM Registry, treatment with the PES resulted in freedom from
MACE and repeat intervention at 1 year in 93.3% and 98.3% of patients [83], respectively; in
the European TRUE Registry, among 183 with CTO treated with PES, 7-months rates of
restenosis and target vessel revascularization were 17.0% and 16.9% respectively [84].
6.2. Sirolimus eluting stents (SES) for CTOs - Registries
Several observational studies examining clinical outcomes among patients treated with DES
following successful CTO recanalization demonstrated the notion that unlike BMS, DES
may achieve similar reductions in the need for repeat target vessel revascularization (TVR),
as observed in non occlusive lesions.
The first data on the effectiveness of SES usage for CTOs came from the Rapamycin Eluting
Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) registry, a prospective sin‐
gle centre study set-up with the aim of evaluating the safety and efficacy of SES in a ‘‘real
world’’ scenario [85]. In this registry SES was the device of first choice for every PCI per‐
formed at the Thoraxcenter irrespective of patient or lesion characteristics. Among 56 pa‐
tients treated with SES following successful CTO revascularization during the first months,
the 1-year survival free of major adverse cardiac events (MACE) defined as the composite of
death, acute myocardial infarction or TVR was 96.4% compared with 82.1% among an his‐
torical control group of 28 patients receiving bare metal stents (p < 0.05). Six-month follow
up angiography performed in 33 patients treated with SES showed a remarkable suppres‐
sion of neointimal proliferation, with in-stent late loss of 0.13±0.46, a binary restenosis rate of
9% and a single reocclusion (3%).
More recently, the RESEARCH investigators have reported the 3-year clinical and angio‐
graphic follow-up of patients with CTO in a consecutive series of 147 patients [86], with
comparison between BMS (n = 71) and SES (n = 76). The cumulative event-free survival of
MACE was 81.7% in BMS group and 84.2% in SES group (p = 0.7). The authors concluded
that, despite clinical benefit after 1 year, the use of SES was no longer associated with signifi‐
cantly lower rates of TVR and MACE in patients with CTOs after 3 years of follow-up com‐
pared with BMS. The issue of long term outcome after successful CTO revascularization and
DES implantation will surely continue to deserve attention in the future.
Percutaneous Recanalization of Chronic Total Occlusion (CTO) Coronary Arteries: Looking Back and Moving Forward
http://dx.doi.org/10.5772/54079
451
Ge et al. provided other insights into the angiographic and clinical impact of implantation of
SES in the re-opened CTOs [87]. The results of a group comprised of 122 patients treated
with SES were compared with a historical control group of 259 patients treated for the same
kind of lesions during an antecedent 2-year period. Coronary enzyme release during the
procedures was insignificantly different despite considerably longer stented segments in the
SES treated group. At 6-month follow-up, the cumulative rate of MACE was 16.4% in the
SES group and 35.1% in the BMS group (p<0.001), whereas the incidence of restenosis was
9.2% and 33.3% (P<0.001) in SES vs BMS, respectively. The need for revascularization in the
SES group was significantly lower, both for target lesion revascularization (TLR) (7.4 vs.
26.3%, P<0.001) and TVR (9.0 vs. 29.0%, P<0.001). No differences were observed between the
groups in the occurrence of death, myocardial infarction, or stent thrombosis in the 6-month
observation period.
The e-CYPHER was a registry designed to capture postmarketing surveillance data on the
use of SES. Between April 2002 and September 2005, data on 15,157 patients treated with
SES at 279 centers from 41 countries were entered into the registry. From the total amount of
patients enrolled in the registry, 6-month follow-up data were available for 10,962 patients.
A sub-analysis [88] assessed the outcomes of CTO, defined as an occlusion lasting > 3
months. A total of 415 patients were identified, representing 2.9% of the total population.
When their results were compared with those ones seen for the rest of the patients enrolled
in the registry, there was no difference regarding death, myocardial infarction, TLR, or
MACE. Investigators concluded that the event rates were similar for patients with CTO
treated with the SES and patients treated for other lesion types, with a low rate of TLR
(2.9%) and MACE (6.5%) in the CTO group at 6-month follow-up.
The Sirolimus-eluting Stent in Chronic Total Occlusion (SICTO) study was a multicentre,
prospective, non-randomized study of coronary stenting with SES in patients with CTOs
[89]. A total amount of 25 patients was treated with the SES stent after successful balloon
angioplasty and IVUS examination. At 6-month angiographic and IVUS follow-up, the use
of the SES stent was associated with improvements both in reference vessel diameter and
minimum lumen diameter. In addition, the rate of in-stent late loss was -0.1 ± 0.3 mm and
percent stent plaque volume was 13.1 ± 18.4%. The number of events at 6 months was also
very low, with no deaths, myocardial infarction, stent thrombosis, or target lesion revascula‐
rization. There were 2 cases of target vessel revascularization (8%).
As a part of a multicentre Asian registry evaluating DES, Nakamura et al. investigated clini‐
cal and angiographic outcomes in 60 patients who received SES and 120 patients who re‐
ceived BMS [83]. After 6 months, the SES group still had significantly lower restenosis and
reocclusion rates (2% and 0%, respectively) than did the BMS group (32% and 6%, respec‐
tively). Afterwards the loss was significantly smaller in the SES group than in the BMS
group. Moreover, the SES group had fewer cardiac events, including target lesion revascula‐
rization (2% vs 23%, p < 0.001), than the BMS group did. At 1 year, treatment with SES was
associated with sustained reductions in hierarchical MACE and TLR.
The ACROSS/TOSCA 4 (Approaches to Chronic Occlusions with Sirolimus-Eluting Stents/
Total Occlusion Study of Coronary Arteries 4) study was amulticenter, non randomized pro‐
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spective trial, which esamining the safety and efficacy of SES in CTOs PCI. In this study, the
6-months binary restenosis rates were 9.5% in-stent, 12.4% in-segment, and 22.6% in-“work‐
ing lenght” representing the entire treatment segment. Rates of 1-year target lesion revascu‐
larization, MI and target vessel failure were 9.8%, 1.0% and 10.9%, respectively. Stent
thrombosis occurred in two patients (1.0%) [90].
More recently, Galassi et al. have published the results of SECTOR (Sirolimus-Eluting Stent
in Complex Coronary Chronic Total Occlusion Revascularization) Registry designed to as‐
sess angiographic and clinical outcomes after sirolimus-eluting stent (SES) implantation in
the setting of a "real world" series of complex CTOs [91]. In this registry, the 9-12 months
angiographic follow-up performed in 85.5% of lesions showed a binary restenosis rate of
16.8%. Moreover, at 2-year clinical follow-up, the rates of target lesion revascularization,
non-Q wave MI, and total MACE were of 11.1%, 2%, and 13.1%, respectively.
6.3. Sirolimus eluting stents for CTOs - Randomized trials
The PRISON II [92] has been the first randomized trial performed to compare DES and BMS.
PRISON II addressed a primary end point of angiographic binary restenosis at six months
and secondary end points of MACE, target vessel failure (TVF), in-stent and in-segment
mean luminal diameter (MLD), late lumen loss, late-loss index, and percent diameter steno‐
sis at six months. A total of 200 patients were randomized to a bare BX Velocity stent or to
the SES. In-stent restenosis results were 7% for the SES patient cohort vs. 36% for the pa‐
tients in the bare metal control arm of the study (p <0.001). The SES also achieved statistical
significance in key clinical endpoints such as target lesion revascularization (4% vs. 19%;
p=0.001); TVF (8% vs 24%; p= 0.003) and MACE (4% vs 20%; p<0.001). In-stent late loss in the
SES patient cohort was 0.05 mm and 1.09 mm in the control (p=0.0001). Such strong evidence
from a well-conducted randomized study has provided clear evidence of efficacy of the SES
and follow up is awaited to evaluate the long term outcomes.
Long term results of PRISON II were recently published [93]. At 5-year follow-up, event
rates still favoured the SES arm over the BMS arm. In fact, SES group had significantly lower
rates of target lesion revascularisation (12% vs. 30%, p=0.001), target vessel revascularisation
(17% vs. 34%, p=0.009) and MACE (12% vs. 36%, p<0.001). There were no significant differ‐
ences in death and myocardial infarction. On the other hand, there is a trend to a higher
stent thrombosis rate in the SES group (8% vs. 3%, p=0,21).
The CORACTO study [94] was performed to evaluate the sirolimus-coated CURA stent in
95 patients with a CTO of > 3 months duration. Patients were randomized to treatment with
either the CURA stent or BMS implantation; the primary end-point was late loss and reste‐
nosis at 6 months. Follow-up angiography demonstrated significant differences between the
two groups in favour of CURA stents. The mean late loss was 1.46 mm in those treated with
BMS vs 0.41 mm in the CURA stent group (p<0.001). The suppression of neointimal prolifer‐
ation was associated with less restenosis, reocclusion, and need for TVR. No patient died or
suffered a stent thrombosis or myocardial infarction.
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6.4. Comparative DES trials in CTOs revascularization
The clinical outcomes of both SES and PES for the treatment of CTO were further analyzed
in the registry data from Rotterdam [95]. A cohort of 76 patients was treated with SES; sub‐
sequently, in the first quarter of 2003, all patients were treated with PES, including 57 treat‐
ed for a CTO. These patients were compared with a similar group of patients (n=26] treated
with BMS in the 6-month period preceding April 2002. At 400 days, the cumulative survival-
free of target vessel revascularization was 80.8% in the BMS group versus 97.4% and 96.4%
in the SES and PES groups respectively (p=0.01). The authors concluded that the use of both
the SES and PES in the treatment of CTOs reduces the need for repeat revascularization
compared to BMS.
Another report by Jang et al. involved 107 patients with CTO who received SES, and 29
patients with CTO who received PES [96]. At 6-month angiographic follow up, the reste‐
nosis rate was significantly higher in the PES group (28.6% vs. 9.4%; p = 0.02). Similarly,
the late loss was significantly higher in the PES group (0.8  mm vs.  0.4  mm; p = 0.025).
At one-year follow up,  the MACE-free survival  rate was significantly higher in the SES
group (95.8% vs. 85.8%; p = 0.049).
Recently, a randomized study evaluating SES and PES has been performed by De Lezo et al
[97]. No significant differences were reported between SES and PES in the rates of restenosis
(7.4% versus 19%, respectively) and TLR (3.3% versus 7.0%). However, the PES group was
found to have a significantly higher late loss and neointimal area on intravascular ultrasound.
At 15 months, death and myocardial infarction rates were comparable between the two stents.
A prospective analysis of 1149 patients with 1183 CTOs (396 SES, 526 PES, 177 ZES, 64 EPC
capture, 43 EES) in five high volume Asian centers after successful recanalization of CTO
was recently performed [98]. The study endpoints were 30 days and 9 months MACE, 9
months angiographic restenosis and TLR. In this series patients treated with SES showed
lesser rate of restenosis compared with other drug-eluting stents.
PRISON III ongoing trial will address whether or not SES are superior to other drug-eluting
stents in total coronary occlusions. Indeed this prospective, randomized trial, SES implanta‐
tion will be compared with zotarolimus-eluting stent implantation for the treatment of total
coronary occlusions. A total of 300 patients will be followed for up to 5 years with angio‐
graphic follow-up at 8 months. The primary end point will be in-segment late luminal loss
at 8 months angiographic follow-up [99].
A new randomised ongoing trial, the Non-Acute Coronary occlusion treated by EveroLi‐
mus-Eluting Stent (CIBELES) trial, aims to compare everolimus-eluting stent and sirolimus-
eluting stent in treating CTOs, in terms of angiographic efficacy [100].
6.5. Optimization of stent deployment
The introduction of stent delivery systems, which used semi-compliant balloons to deploy
stents at higher pressures, initially resulted in less use of balloon post-dilatation. However, it
was soon recognized that adjunctive balloon post-dilatation following deployment of BMS im‐
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proved stent expansion in its entire length and resulted in better outcomes with less need for
TVR [101-103]. Consequently, post-dilatation has been widely, although not universally, used.
With the advent of DES and much lower rates of TVR, there has been renewed controversy re‐
garding the need for adjunctive balloon post-dilatation to optimize outcomes. However DES
thrombosis, which might be related to procedural variables, such as minimal stent area (MSA)
and stent expansion following stent deployment, makes a come back the role of post-dilata‐
tion. Indeed, the frequency of stent thrombosis following DES implantation is relatively low
[104-105], but the clinical sequeale of stent thrombosis are catastrophic and include death in
about 45% of patients and non-fatal myocardial infarction in most of the survivors [106].
Similarly to stent thrombosis, maximizing MSA appears important in reducing the risk of
TVR. This should be theoretically even more important in case of long standing CTO where
severe and diffuse disease in presence of extensive calcification might prevent adequate
stent expansion [107].
The inability to achieve optimum stent deployment is not due to undersizing the stent deliv‐
ery balloon, but rather due to an inability of the stent delivery balloon to expand fully the
stent to nominal size. With postdilatation using noncompliant balloons, the frequency of
achieving optimum stent deployment doubles [108].
Lesions with heavy calcification or large plaque burden, such as CTO lesion, are likely to
have increased resistance to dilatation. In such situations, inadequate stent expansion may
be evident from the contour of the deployment balloon or the angiographic appearance of
the stent post stent deployment. However, inadequate stent expansion is usually not detect‐
able by angiographic assessment. In situations where there is likely to be increased resist‐
ance to dilatation, postdilatation with noncompliant balloons at high pressure appears to be
a good strategy.
Theoretically, in an attempt to minimize stent thrombosis and TVR, post-dilatation with
non-compliant balloons should be performed by IVUS guidance. Unfortunately, it is not
practical and probably not cost-effective to perform IVUS and post-dilatation to all patients
undergoing DES implantation. Moreover after DES implantation in long CTO lesion with
multiple stents overlapping is recommended to perform post-dilatation with non compliant
balloon in order to improve MSA and thus to obtained a good angiographic outcome.
Post-dilatation can improve significantly MSA within the limits of reference vessel size even
if it is still likely not to affect non-uniformity expansion. An uniform stent expansion may be
achieved with either adequate pre-dilatation or by the use of rotational atherectomy in calci‐
fied lesions to allow the simmetricity expansion of the lesion by the balloon and stent.
7. Complications of CTO PCI
The PCI CTO procedural complications can be classified as follows: vascular access related
and procedure related. Despite the development of new devices and techniques, complica‐
tions still occasionally occur today. This is highlighted by the complications reducing with
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improved learning curve. Therefore, the operator’s experience is essential in order to quickly
recognise and handle all sorts of complications.
7.1. Complications vascular access related
Access site complications are common during intravascular procedure and include hemato‐
mas of any size, pseudoaneurysm, and artero-venuos fistulae [109]. Despite of the need of
large size sheath and double coronary cannulation, both femoral vascular access are general‐
ly recommended during CTO PCI. Some operators prefer to place two sheaths in the same
femoral artery, in order to reduce patient discomfort (Figure 8) however, this approach re‐
strict the use up to smaller size sheaths and might limit the use of closure device after proce‐
dure thus increasing the occurrence of rare complication such as acute limb ischemia.
Figure 8. Two 6 French sheath in a femoral artery
Such complications are more frequent in older, female, overweight or previously anticougu‐
lated patients, and can be prevent by careful puncture, compression technique and 6-12
hours bed rest after procedure. Small hematomas are common (2-15%) and usually produce
only mild discomfort for a few days. Large hematomas (>10 cm) are less frequent (1-2%) and
might require prolonged rest and a delay in hospital discharge; the complete resolution,
thus may take in 3-4 weeks. Diagnosis can be based on clinical features (no femoral mur‐
mur) and confirmed by a Doppler study performed with standard echocardiography equip‐
ment. Occasionally, large hematomas become infected, and in this case is important to
surgically drain the cavity by purulent materials. This may take 2-3 months to heal.
Uncontrolled bleeding (either evident or into retroperitoneal space) with severe haemodi‐
namic compromise require aggressive fluid blood replacement, ruling out bleeding from an‐
other origin. In these cases vascular surgery might resolve the complications.
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Femoral pseudoaneurysm and artero-venuos fistulae might occur in case of low puncture
(more than 2 cm below the inguinal ligament). Diagnosis is based on clinical grounds (the
presence of hard and pulsatile mass in the case of pseudoaneurysm and the presence of con‐
tinuous murmur in case of an artero-venous fistulae) and confirmed by Doppler examina‐
tion. In most cases pseudoaneurysm can be closed successfully with femoral compression
guided by echocardiography followed by bed rest for 12-24 hours after discontinuation of
antithrombotic medication.
Dissection can be caused by the wire or the sheath at the access site and can extend retro‐
gradely upward in to the vascular system; this occurs more frequently in older and hyper‐
tensinve patients with marked aortic tortuosity and may cause limb ischemia.
7.2. Complications procedure related
Complications directly related to CTO procedure might be summarized in: coronary perfora‐
tion or rupture, coronary ostium dissection, coronary thrombosis and entrapment of device into a le‐
sion. Among these complications, coronary perforation is associated with different adverse
cardiac event such as myocardial infarction and cardiac tamponade. Although coronary per‐
foration accounts for 10% of total referrals for emergent cardiac surgery, it is most common‐
ly managed in the catheterization laboratory with different approach. Several large PCI
series shows an incidence of coronary perforation below 1% [110-113], and the presence of a
CTO does not seem to increase significantly this value [114].
7.3. Coronary perforation
During PCI, coronary perforation is one of the most undesirable complications because it is
occasionally life-threatening by causing cardiac tamponade or acute myocardial infarction
[110-113]; it represents a disruption of the vessel wall through the intima, media and adven‐
titia. Coronary perforations risk factors during standard PCI can be classified as patient relat‐
ed, angiographic related and device and/or procedure related. In term of patient-related risk several
studies found that older age and female gender are associated with an increased incidence
of coronary perforation [107, 108, 115].
Angiographic related risk factors are represented by heavy calcification and innaccurate as‐
sessment of vessel diameter size. Indeed, these lesions require often the use of multiple bal‐
loon dilatations coupled with relatively high inflation pressure, before and/or after stent
implantation, in order to achieve full stent expansion. These might cause vessel wall perfo‐
ration, especially when are used compliant or semi-compliant balloon. In a study of Tobis et
al. the use of a high balloon to vessel ratio (1.2:1) with a mean inflation pressure of 15 atm
determined an incidence of vessel rupture and major dissection of approximately 3-4% of
the cases [116]. In the same study, the use of a smaller balloons, in a different subgroup, but
with higher mean inflation pressure (16 atm) was associated with reduction of coronary per‐
foration rate (0.7%) [116]. For these reasons, we suggest to use small diameter size balloon
when performing PCI in CTO lesion.
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Among device and/or procedure related complications several authors have shown that the use
of atheroblative debulking devices (laser, rotational atherectomy, directional coronary atherectomy)
might be associated with coronary perforation [112-113]. Other devices such us cutting bal‐
loon, IVUS probe, extraction catheters and embolic protection device might also enhance the
likelihood of coronary perforation, as well as stiffer and/or hydrophilic wires that are rou‐
tinely used for CTO recanalization. During the procedure is important to follow the path of
the guide wire in multiple orthogonal projection, in order to recognize promptly site of ves‐
sel wall apart or segment of sub-intimal tracking.
Perforation due to stiff wires are divided in two categories: perforation of the false lumen
while advancing the stiff wire into it, and perforation in distal small branch after crossing
CTO lesion. Generally the first type of perforation do not require a specific treatment be‐
cause it disappears after dilatation on another false lumen. Conversely in distal small branch
perforation a careful observation through multiple contrast injection are needed to confirm
the risk related to perforation. Indeed, these might lead to early or late cardiac tamponade.
Thus, is recommended at the end of procedure, even if in successful cases, to perform at
least two orthogonal cine angiograms to exclude the presence of it.
Ellis et al., on the basis of prospectively recorded data of a total of 12.900 PCI procedure
from 11 US sites during a 2-year period [110], were able to drawn a coronary perforation
classification related to the angiographic appearance of blood extravasation during the pro‐
cedure in four types:
• Type I, perforation with extaluminal crater without extravasation
• Type II, pericardial or myocardial blush without contrast jet extravasation
• Type III, extravasation through frank (≥ 1mm) perforation
• Type IV (cavity spilling) perforation into anatomic cavity chamber, coronary sinus, etc.
In addition this study evaluated its proposal classification system as a tool to predict out‐
come and as the basis management as follow:
• Type I: fully contained perforation rarely result in tamponade or in myocardial ischemia
• Type II: limited extravasation perforation have high treatment success rate when man‐
aged with prolonged balloon inflation, and commonly have a low occurrence of persistent
contrast extravasation, consequently resulting in a low incidence of adverse sequelae
• Type III: brisk extravasation perforation are associated with rapid development of hemo‐
dynamic compromise and life-threatening complication, include cardiac tamponade and
the need for emergent bypass surgery with high rate of mortality
Myocardial infarction and the majority of emergent CABG and cardiac tamponade were
entirely  limited  of  type  III  perforation  [113].  Coronary  perforation  is  associated  with  a
significant mortality risk; its management and treatment need to be initiated very quick‐
ly.  The  strategy  of  treatment  is  determinate  by  angiographic  characteristics  and clinical
circumstances [115].
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In case of type I perforation,  the retrieval of guidewire is sufficient to cope with the com‐
plication. In other cases a prolonged (3-5 minutes) proximal balloon inflation or stent im‐
plantation  might  help  to  solve  the  problem.  However,  a  careful  observation  for  15-30
minutes with repeated injection of contrast mean is highly recommended. If the extrava‐
sation  enlarges  during  time,  intravenous  administration  of  protamine  sulfate  is  advised
in  order  to  neutralizing  the  anticoagulant  effect,  as  patients  performing  CTO  PCI  are
treated  by  unfractioned heparin  alone.  Generally  re-administration  of  protamine  sulfate
is  given intravenously over a 3–5 min time period for obtaining a ACT target  less than
150 seconds as reported [112-115]. Moreover, it is to remember that protamine sulfate ad‐
ministration  is  safe  in  case  of  BMS implantation  [117]  but  it  might  cause,  albeit  rarely,
stent thrombosis with potential fatal consequences, in case of DES use [118].
In type II perforation, proximal balloon inflation and reversal of anticoagulation with prota‐
mine sulfate are the first actions to take. Echocardiographic assessment should be performed
without delay; early diastolic right ventricular collapse and late diastolic right atrial collapse
are early signs of cardiac tamponade and precede the haemodinamic instability. If these
signs are observed urgent pericardiocentesis should be recommended and this is an action
to be taken immediately after recognition of the perforation and before clinical symptoms
develop. A placement of coronary perfusion catheter (CPC) balloon might be indicated, if
after 5-10 minutes of proximal balloon inflation the seal of perforation does not occur. The
passive CPC balloon has been initially developed to allow demands of the myocardium at
risk, for prolonged inflation in patients with rigid artery stenosis [119] and later modified to
seal coronary perforation. Several types of this device have the same principle design which
consist of side-holes in the shaft of the catheter proximal and distal to the balloon, allowing
passive blood perfusion during balloon inflation, depending on the aortic perfusion pres‐
sure. Perfusion catheters provide a blood flow of 40-60 ml/minutes to the region at risk
[119]. Nevertheless, a significant number of patients do not tolerate prolonged inflation peri‐
ods, either because of obstruction of a side branch or due to inadequate flow relative to the
demands of the myocardium at risk. Therefore the CPC balloon devices might be used in
preparation of emergent cardiac surgery [120], reducing pericardial blood blush and Q wave
myocardial infarction occurrence. Emergent cardiac surgery is reserved for patients in
whom hemostasis is not achieved with these measures.
The  onset  of  type  III  perforation  is  usually  dramatically:  an  immediate  aggressive  treat‐
ment strategy is needed, including adequate volume resuscitation, administration of cate‐
cholamines  and  urgent  pericardiocentesis.  Obviously,  a  proximal  balloon  inflation  and
heparin reversal is also needed immediately; and after the stabilization of patient clinical
status a placement of covered stent (in case of epicardial  coronary rupture) or synthetic
microsphere  embolization  (in  case  of  distal  perforation)  might  seal  the  perforation
[111-115]. In case of perforation resolution is advisable a careful post-procedure echocar‐
diograms monitoring, before pericardial  catheter removal and at discharge.  The figure 9
reports  a  practical  algorithm  for  the  management  of  coronary  perforation  adapted  by
Dippel and colleagues [121] (Figure 9)
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Figure 9. Algorithm of coronary perforation management in relation to angiographic type; adapted by Dippel et. al
7.4. Coronary ostium dissection
The need of high back-up force in CTO PCI, make the choice of guiding catheter very impor‐
tant. Several high back-up guiding catheters, such as Amplatz, could injure the coronary os‐
tium, causing flow limiting tubular dissection. Indeed, “maladroit” manipulation of guiding
catheter or its deep intubation might also cause ostium dissection. This event happens fre‐
quently in the right coronary artery in case of proximal vessel disease. Thereafter in these
case is recommended to stabilized the ostium and the proximal part of the vessel with stent
implantation prior to beginning CTO PCI. Particular attention might give at the cannulation
of donor vessel in case of retrograde approach. Indeed a dissection in the donor vessel might
cause severe peri-procedural events.
7.5. Coronary thrombosis
The use of complex technique, such as retrograde approach and the use of multiple guide
wire and device might added the risk of coronary thrombosis. Thus, after administration of
initial bolus of 80-100 Units/Kg is recommended checking the ACT every 30 minutes main‐
taining the ACT >300 seconds (>350 second in case of retrograde approach). Indeed, careful
observation in an angiogram might help to recognize early phase of coronary thrombosis. If
a thrombus is observed, is advisable to abort the procedure, take away the double cannula‐
tion and resolve the situation with use of aspiration device and Gp IIb/IIIa inhibitors admin‐
istration. Distal embolization resulting in slow-flow phemonenon is very frequent after CTO
balloon dilatation; in these cases intracoronary administration of vasodilatator such as ade‐
nosine of nitroprusside could improve coronary flow significantly.
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7.6. Entrapment of device inside a lesion
Entrapment of device such as microcatheter or standard balloon might occur after CTO wire
crossing especially in highly calcified and tortuous vessel. Several dedicated devices such as
Tornus catheter, Corsair and Gopher might rarely stuck into the vessel in severe calcified le‐
sions. Such an evenience might be approached by the see saw technique with stiff wires; in‐
deed, the use of another stiff wire might find the way of a new dissection plane at the
blocking site, breaking the calcium load which grapped the device. During retrograde ap‐
proach, in case of very tortuous collaterals it is also possible entrapment of guide wire with‐
in the coronary artery. In these cases attention should be paid not to twist the wire into
collaterals, as solution to this complication is only surgery.
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